Is Regencell Bioscience Stock a Good Investment?
Regencell Bioscience Investment Advice | RGC |
- Examine Regencell Bioscience's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Regencell Bioscience's leadership team and their track record. Good management can help Regencell Bioscience navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Regencell Bioscience's business and its evolving consumer preferences.
- Compare Regencell Bioscience's performance and market position to its competitors. Analyze how Regencell Bioscience is positioned in terms of product offerings, innovation, and market share.
- Check if Regencell Bioscience pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Regencell Bioscience's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Regencell Bioscience Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Regencell Bioscience Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Regencell Bioscience Stock
Researching Regencell Bioscience's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 89.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 2.15. Regencell Bioscience recorded a loss per share of 0.33. The entity last dividend was issued on the 1st of December 2017.
To determine if Regencell Bioscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Regencell Bioscience's research are outlined below:
| Regencell Bioscience had very high historical volatility over the last 90 days | |
| Reported Net Loss for the year was (4.36 M) with profit before taxes, overhead, and interest of 0. | |
| Regencell Bioscience Holdings has about 59.41 K in cash with (4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Regencell Bioscience has a poor financial position based on the latest SEC disclosures | |
| Roughly 89.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Regencell Bioscience Shares Drop Amidst Market Volatility |
Regencell Bioscience Quarterly Cost Of Revenue |
|
Regencell Bioscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Regencell Bioscience Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Regencell Bioscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of January 2024 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Know Regencell Bioscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regencell Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regencell Bioscience Holdings backward and forwards among themselves. Regencell Bioscience's institutional investor refers to the entity that pools money to purchase Regencell Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-06-30 | 312 | Blackrock Inc | 2024-06-30 | 238 | Qube Research & Technologies | 2024-06-30 | 13.0 |
Regencell Bioscience's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 82.24 M.Market Cap |
|
Regencell Bioscience's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | 0.05 | |
| Return On Capital Employed | (0.57) | 0.12 | |
| Return On Assets | (0.51) | 0.04 | |
| Return On Equity | (0.52) | (0.13) |
Determining Regencell Bioscience's profitability involves analyzing its financial statements and using various financial metrics to determine if Regencell Bioscience is a good buy. For example, gross profit margin measures Regencell Bioscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Regencell Bioscience's profitability and make more informed investment decisions.
Please note, the presentation of Regencell Bioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Regencell Bioscience's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Regencell Bioscience's management manipulating its earnings.
Evaluate Regencell Bioscience's management efficiency
Regencell Bioscience has Return on Asset of (0.2811) % which means that on every $100 spent on assets, it lost $0.2811. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4318) %, meaning that it generated no profit with money invested by stockholders. Regencell Bioscience's management efficiency ratios could be used to measure how well Regencell Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. At present, Regencell Bioscience's Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.04, whereas Return On Equity is projected to grow to (0.13). At present, Regencell Bioscience's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Return On Tangible Assets is expected to grow to 0.05, whereas Total Assets are forecasted to decline to about 8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.63 | (5.47) | |
| Tangible Book Value Per Share | 0.63 | (7.96) | |
| Enterprise Value Over EBITDA | (10.75) | 8.06 | |
| Price Book Value Ratio | 5.08 | (1.92) | |
| Enterprise Value Multiple | (10.75) | 8.06 | |
| Price Fair Value | 5.08 | (1.92) | |
| Enterprise Value | 38.9 M | 3.2 B |
At Regencell Bioscience, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta (0.60) |
Basic technical analysis of Regencell Stock
As of the 30th of November, Regencell Bioscience holds the Coefficient Of Variation of 24364.1, semi deviation of 6.48, and Risk Adjusted Performance of 0.0123. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regencell Bioscience, as well as the relationship between them.Regencell Bioscience's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regencell Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regencell Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regencell Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kaplan Stephen A over three months ago Acquisition by Kaplan Stephen A of 10000 shares of Regencell Bioscience at 14.87 subject to Rule 16b-3 | ||
Brandow Peter B over six months ago Disposition of 1564 shares by Brandow Peter B of Regencell Bioscience at 22.97 subject to Rule 16b-3 | ||
Amy Miles over six months ago Disposition of 33006 shares by Amy Miles of Regencell Bioscience at 21.58 subject to Rule 16b-3 | ||
Peter Brandow over six months ago Disposition of 1265 shares by Peter Brandow of Regencell Bioscience at 22.87 subject to Rule 16b-3 |
Regencell Bioscience's Outstanding Corporate Bonds
Regencell Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regencell Bioscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regencell bonds can be classified according to their maturity, which is the date when Regencell Bioscience Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Regencell Bioscience's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Regencell Bioscience's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0123 | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 6.3 | |||
| Semi Deviation | 6.48 | |||
| Downside Deviation | 6.57 | |||
| Coefficient Of Variation | 24364.1 | |||
| Standard Deviation | 9.38 | |||
| Variance | 88.03 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.1253 | |||
| Total Risk Alpha | (1.54) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 43.32 | |||
| Value At Risk | (10.93) | |||
| Potential Upside | 22.58 | |||
| Downside Variance | 43.12 | |||
| Semi Variance | 41.95 | |||
| Expected Short fall | (7.74) | |||
| Skewness | 1.71 | |||
| Kurtosis | 3.41 |
| Risk Adjusted Performance | 0.0123 | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 6.3 | |||
| Semi Deviation | 6.48 | |||
| Downside Deviation | 6.57 | |||
| Coefficient Of Variation | 24364.1 | |||
| Standard Deviation | 9.38 | |||
| Variance | 88.03 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.1253 | |||
| Total Risk Alpha | (1.54) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 43.32 | |||
| Value At Risk | (10.93) | |||
| Potential Upside | 22.58 | |||
| Downside Variance | 43.12 | |||
| Semi Variance | 41.95 | |||
| Expected Short fall | (7.74) | |||
| Skewness | 1.71 | |||
| Kurtosis | 3.41 |
Consider Regencell Bioscience's intraday indicators
Regencell Bioscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Regencell Bioscience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Regencell Bioscience Corporate Filings
| 25th of October 2024 Other Reports | ViewVerify | |
6K | 20th of June 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Regencell Stock media impact
Far too much social signal, news, headlines, and media speculation about Regencell Bioscience that are available to investors today. That information is available publicly through Regencell media outlets and privately through word of mouth or via Regencell internal channels. However, regardless of the origin, that massive amount of Regencell data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Regencell Bioscience news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Regencell Bioscience relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Regencell Bioscience's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Regencell Bioscience alpha.
Regencell Bioscience Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Regencell Bioscience can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Regencell Bioscience Corporate Management
| Wai Chung | COO Officer | Profile | |
| Tien Chau | Executive Officer | Profile | |
| Michelle Chan | Financial Controller | Profile | |
| YatPui Au | Chief Officer | Profile | |
| YatGai Au | Chairman Founder | Profile | |
| Antonia Assang | Senior Management | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Regencell Bioscience's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.